Logo image of BOLT

BOLT BIOTHERAPEUTICS INC (BOLT) Stock Fundamental Analysis

NASDAQ:BOLT - Nasdaq - US0977021049 - Common Stock - Currency: USD

5.15  -0.29 (-5.33%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to BOLT. BOLT was compared to 550 industry peers in the Biotechnology industry. While BOLT seems to be doing ok healthwise, there are quite some concerns on its profitability. BOLT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BOLT has reported negative net income.
BOLT had a negative operating cash flow in the past year.
BOLT had negative earnings in each of the past 5 years.
BOLT had a negative operating cash flow in each of the past 5 years.
BOLT Yearly Net Income VS EBIT VS OCF VS FCFBOLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -73.78%, BOLT is doing worse than 65.64% of the companies in the same industry.
Looking at the Return On Equity, with a value of -135.33%, BOLT is doing worse than 61.27% of the companies in the same industry.
Industry RankSector Rank
ROA -73.78%
ROE -135.33%
ROIC N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
BOLT Yearly ROA, ROE, ROICBOLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BOLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BOLT Yearly Profit, Operating, Gross MarginsBOLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

BOLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BOLT has been increased compared to 1 year ago.
BOLT has more shares outstanding than it did 5 years ago.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BOLT Yearly Shares OutstandingBOLT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
BOLT Yearly Total Debt VS Total AssetsBOLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -8.97, we must say that BOLT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.97, BOLT is doing worse than 71.09% of the companies in the same industry.
BOLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.97
ROIC/WACCN/A
WACC9.82%
BOLT Yearly LT Debt VS Equity VS FCFBOLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

BOLT has a Current Ratio of 3.13. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.13, BOLT is not doing good in the industry: 62.91% of the companies in the same industry are doing better.
BOLT has a Quick Ratio of 3.13. This indicates that BOLT is financially healthy and has no problem in meeting its short term obligations.
BOLT has a Quick ratio of 3.13. This is in the lower half of the industry: BOLT underperforms 61.09% of its industry peers.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
BOLT Yearly Current Assets VS Current LiabilitesBOLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

BOLT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.83%.
BOLT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -67.87%.
Measured over the past years, BOLT shows a very strong growth in Revenue. The Revenue has been growing by 103.56% on average per year.
EPS 1Y (TTM)7.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
Revenue 1Y (TTM)-67.87%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%-76.83%

3.2 Future

The Earnings Per Share is expected to grow by 5.75% on average over the next years.
BOLT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.46% yearly.
EPS Next Y21.04%
EPS Next 2Y17.2%
EPS Next 3Y21.16%
EPS Next 5Y5.75%
Revenue Next Year-58.33%
Revenue Next 2Y-31.19%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BOLT Yearly Revenue VS EstimatesBOLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
BOLT Yearly EPS VS EstimatesBOLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BOLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BOLT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BOLT Price Earnings VS Forward Price EarningsBOLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BOLT Per share dataBOLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as BOLT's earnings are expected to grow with 21.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.2%
EPS Next 3Y21.16%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BOLT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BOLT BIOTHERAPEUTICS INC

NASDAQ:BOLT (8/15/2025, 4:30:01 PM)

5.15

-0.29 (-5.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-10 2025-11-10
Inst Owners46.17%
Inst Owner Change-5.69%
Ins Owners0.63%
Ins Owner Change0%
Market Cap9.89M
Analysts74.55
Price Target40.8 (692.23%)
Short Float %4.65%
Short Ratio0.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.76%
Min EPS beat(2)1.96%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)4.58%
Min EPS beat(4)-11.25%
Max EPS beat(4)21.57%
EPS beat(8)7
Avg EPS beat(8)10.98%
EPS beat(12)10
Avg EPS beat(12)10.46%
EPS beat(16)13
Avg EPS beat(16)6.88%
Revenue beat(2)1
Avg Revenue beat(2)-21.95%
Min Revenue beat(2)-100%
Max Revenue beat(2)56.1%
Revenue beat(4)2
Avg Revenue beat(4)-3.78%
Min Revenue beat(4)-100%
Max Revenue beat(4)56.1%
Revenue beat(8)5
Avg Revenue beat(8)21.57%
Revenue beat(12)9
Avg Revenue beat(12)49.64%
Revenue beat(16)12
Avg Revenue beat(16)46.05%
PT rev (1m)0%
PT rev (3m)3455.56%
EPS NQ rev (1m)-2.93%
EPS NQ rev (3m)-1778.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-1560.2%
Revenue NQ rev (1m)-25.01%
Revenue NQ rev (3m)-16.97%
Revenue NY rev (1m)-18.05%
Revenue NY rev (3m)24.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.72
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-30.6
EYN/A
EPS(NY)-19.04
Fwd EYN/A
FCF(TTM)-30.18
FCFYN/A
OCF(TTM)-30.16
OCFYN/A
SpS1.89
BVpS24.38
TBVpS24.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.78%
ROE -135.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.44%
ROA(5y)-61.59%
ROE(3y)-74.37%
ROE(5y)-4101.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -8.97
F-Score2
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)43.39%
Cap/Depr(5y)172.25%
Cap/Sales(3y)12.39%
Cap/Sales(5y)328.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.57%
EPS Next Y21.04%
EPS Next 2Y17.2%
EPS Next 3Y21.16%
EPS Next 5Y5.75%
Revenue 1Y (TTM)-67.87%
Revenue growth 3Y82.75%
Revenue growth 5Y103.56%
Sales Q2Q%-76.83%
Revenue Next Year-58.33%
Revenue Next 2Y-31.19%
Revenue Next 3Y13.16%
Revenue Next 5Y14.46%
EBIT growth 1Y15.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-71.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y23.4%
OCF growth 3YN/A
OCF growth 5YN/A